Ask a hospital CFO how much their organization spends on labor and they will give you a precise number. Ask the same CFO for a breakdown of pharmacy spend by formulary tier, therapeutic category, contract compliance rate, and 340B capture efficiency and most will give you a single aggregate figure with none of the granularity that would make it manageable.
This is an architectural reality, not a leadership failure. Pharmacy spending in most health systems sits at the intersection of the EHR, the pharmacy information system, the GPO contract database, the 340B administration platform, and the payer formulary structure, and none of these systems were built to produce a coherent financial picture together.
The result is a cost category growing faster than almost any other budget line while remaining analytically opaque to the finance teams responsible for governing it.
According to Strata Decision Technology's Monthly Healthcare Industry Financial Benchmarks report, which draws data from more than 1,850 hospitals, drug costs at US hospitals jumped 9.8% in June 2025 compared to June 2024, outpacing total labor expense growth and continuing a sustained trend of pharmaceutical costs rising faster than nearly every other expense category.
For health systems operating on thin margins, a cost category growing at that rate without a structured governance layer is a financial risk that deserves the same rigor applied to labor costs and utilization management.
Why Drug Cost Management Is Not Simply a Pricing Problem
The instinct is to frame pharmacy cost as a drug price problem, something negotiated with manufacturers through the GPO and largely outside the health system's direct control. That framing misses the levers that are actually available and highly actionable.
The four most impactful financial levers in pharmacy cost management are:
- Contract compliance — ensuring purchasing patterns stay within GPO negotiated rates rather than drifting to above-contract prices through emergency procurement or supply shortage workarounds
- Formulary adherence — tracking whether prescribers are consistently choosing the preferred therapeutic agents within each drug class
- Therapeutic substitution governance — identifying where evidence-based switching to a lower-cost equivalent is clinically appropriate and not being acted on
- 340B program optimization — capturing the full financial benefit of eligible dispenses while maintaining continuous compliance
Without item-level business intelligence connected to GPO contract pricing data, contract drift accumulates invisibly until an audit surfaces it months later. These are the levers that a structured pharmacy spend analytics program governs continuously rather than retrospectively.
340B Program Governance: The Compliance and Revenue Intelligence Gap
For eligible health systems, the 340B Drug Pricing Program is one of the most financially significant and analytically complex components of pharmacy management.
The program allows covered entities to purchase outpatient drugs at significantly discounted acquisition costs, and for many organizations that financial benefit is embedded in the operating model as a structural revenue contributor.
In 2024, 340B covered entities purchased $81.4 billion in drugs through the program, with just 10 drugs including oncology, multiple sclerosis, and HIV therapies accounting for $25.36 billion, roughly 30% of the total program spend, according to Medical Economics citing HRSA data.
The Two Compliance Risks That Carry the Most Financial Exposure
The compliance risks in 340B carry audit consequences that most health systems are not continuously monitoring for:
- Diversion risk — the dispensing of 340B drugs to patients who do not qualify for the program
- Duplicate discount risk — claiming both 340B pricing and Medicaid rebates for the same drug dispensing event
Artificial intelligence and machine learning models applied to eligibility data, dispense records, and acquisition cost data produce the real-time compliance view that manages both risks continuously rather than through periodic manual review.
The same infrastructure also optimizes capture rates by identifying eligible patient encounters where 340B pricing was not applied due to eligibility tracking or contract pharmacy coordination gaps, and for high-volume programs, improved capture rates represent a material and immediate financial return.
Specialty Drug Spend and Formulary Compliance
Specialty drugs are the fastest-growing and analytically least governed pharmacy subcategory. They carry high per-unit costs, narrow therapeutic indications, and significant prescribing variability between physicians treating clinically comparable patients, and that variability is where financial exposure concentrates most visibly.
What Specialty Drug Analytics Actually Surfaces
Healthcare analytics software applied at the specialty drug level produces intelligence across three dimensions:
- Prescribing patterns by therapeutic category and prescriber compared against formulary-preferred alternatives
- Per-episode cost differentials between formulary-compliant and off-formulary therapeutic choices for comparable patient cohorts
- Biosimilar utilization gaps by therapeutic area where a lower-cost equivalent is available but adoption has not followed
As biosimilar availability has expanded across oncology, rheumatology, and gastroenterology categories, the financial return on analytics-driven adoption modeling has become increasingly direct and quantifiable.
The Payer Formulary Layer
When a health system's formulary choices do not align with preferred tiers in dominant payer contracts, the downstream consequences are operational and financial simultaneously:
- Prior authorization volumes increase
- Step therapy requirements create prescribing friction and administrative cost
- Specialty drug claims denial rates rise for drugs that could have been approved under a different formulary choice
Healthcare analytics consulting that maps prescribing patterns against payer formulary structures connects pharmacy cost management to contract performance in a way most health systems are currently managing in entirely separate conversations.
Building the Data Foundation That Makes This Possible
The analytics layer connecting all of these pharmacy cost levers is only as good as the data engineering work underlying it. Each source system contains part of the picture. None of them contain the whole picture in isolation.
Data engineering work that unifies the following sources into a single structured environment is the foundational step that makes pharmacy spend analytics financially meaningful:
- Pharmacy information system records
- EHR prescribing data by physician and therapeutic category
- GPO contract pricing databases
- 340B administration platform eligibility and dispense records
- Payer formulary tier structures by contract
Once that foundation is in place, the reporting layer surfaces total drug spend by category with trend lines, GPO contract compliance rates, 340B capture and compliance status, specialty drug spend by therapeutic area and prescriber, and formulary compliance by unit, all in the same reporting cadence as labor and supply chain data.
That is pharmacy spend managed as a CFO metric, not a departmental operational concern.
This shift from fragmented reporting to proactive financial intelligence is also reshaping revenue cycle management, where health systems are moving beyond denial tracking toward predictive models that prevent revenue leakage before claims are submitted.
For a deeper view of this approach in practice, see our blog Beyond Denial Management: Building a Proactive RCM Analytics Program That Prevents Revenue Loss Before It Occurs.
Frequently Asked Questions
What financial questions does pharmacy spend analytics answer?
It answers where off-contract purchasing is creating avoidable cost premiums, which prescribers are driving the highest off-formulary specialty spend, what the 340B capture rate is, and where eligible dispenses are being missed.
How does 340B analytics reduce compliance risk?
It tracks patient eligibility at the encounter level, monitors contract pharmacy transactions for diversion and duplicate discount risk continuously, and surfaces risk before it becomes an audit finding rather than after. This replaces periodic manual audits with a real-time compliance layer.
Can pharmacy analytics connect to existing systems?
Yes. The analytics layer ingests data from existing pharmacy systems, GPO databases, EHR prescribing records, and 340B platforms rather than replacing them. Ascend Analytics manages all source system integration as part of the engagement.
What is a realistic return on a pharmacy spend analytics program?
The primary levers are off-contract purchasing reduction, improved 340B capture rates, formulary compliance improvement in specialty categories, and biosimilar adoption. For health systems with active 340B programs, even modest improvement across these levers typically produces a return that is a multiple of the analytics investment cost within the first operating year.
Is Pharmacy Spending Growing Faster Than Your Ability to Manage It?
The data needed to govern pharmacy spend as a financial variable already exists inside your systems. What is missing is the analytical layer that gives finance leaders a clear, actionable view of drug spend alongside other key financial metrics.
In 2026, with pharmaceutical expenses outpacing nearly every other hospital cost category, that visibility is a margin protection priority.
The team at Ascend Analytics helps organizations gain greater visibility into pharmacy spend and program performance. Connect with us via discovery call today to begin the conversation.
.png)
